Top entities: DBV Technologies, Daniel Tassé, H.C. Wainwright & Co., Nasdaq-100, Euronext Paris.

What category does this event fall under?

Business — classified as investor conference.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

DBV Technologies announced participation · Daniel Tassé will participate

Is this event still developing?

This is an active story, last updated May 12, 2026. Coverage continues to evolve.

Business investor conference

DBV Technologies to attend BioConnect

Q: When did this event occur?

First reported May 12, 2026; last updated May 12, 2026.

Q: What is the market impact?

Direct. The announcement of DBV Technologies' participation in an investor conference could positively impact investor perception and potentially its stock price, as it provides a platform to communicate its biopharmaceutical developments.

Analysis based on 6 articles · First reported May 12, 2026 · Last updated May 12, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The announcement of DBV Technologies' participation in an investor conference could positively impact investor perception and potentially its stock price, as it provides a platform to communicate its biopharmaceutical developments. This event offers an opportunity for DBV Technologies to attract new investors and strengthen its market position.

Biotechnology Pharmaceuticals

Event Summary

DBV Technologies, a late-stage biopharmaceutical company, announced that its Chief Executive Officer, Daniel Tassé, will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq-100 on May 19, 2026. The company, which develops treatments for food allergies using its VIASKIN patch technology, will use this platform to present its ongoing clinical trials and developments. A live webcast and replay of the fireside chat will be available on DBV Technologies' investor website. DBV Technologies' shares are traded on Euronext Paris and Nasdaq-100.

Key Actions

90 DBV Technologies announced participation

80 Daniel Tassé will participate

Entities Involved

stock

DBV Technologies

DBV Technologies announced its CEO, Daniel Tassé, will participate in an investor conference, providing an opportunity to present its biopharmaceutical developments and potentially attract investors.

Importance 100 Sentiment 10

per

Daniel Tassé

Daniel Tassé, CEO of DBV Technologies, will represent the company at the H.C. Wainwright 4th Annual BioConnect Investor Conference, delivering a fireside chat.

Importance 70 Sentiment 0

priv

H.C. Wainwright & Co.

H.C. Wainwright & Co. is hosting the BioConnect Investor Conference where DBV Technologies will participate.

Importance 40 Sentiment 0

index

Nasdaq-100

Nasdaq-100 is the location for the H.C. Wainwright 4th Annual BioConnect Investor Conference, and DBV Technologies' ADSs are traded on the Nasdaq-100 Capital Market.

Importance 30 Sentiment 0

exch

Euronext Paris

DBV Technologies' ordinary shares are traded on Euronext Paris.

Importance 20 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard